MG 98
Alternative Names: HYB 101584; MG-98Latest Information Update: 25 Jan 2024
Price :
$50 *
At a glance
- Originator MethylGene
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action DNA methylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Head and neck cancer; Myelodysplastic syndromes; Renal cancer; Solid tumours
Most Recent Events
- 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
- 20 Mar 2008 Discontinued - Phase-I for Solid tumours in United Kingdom (Injection)
- 20 Mar 2008 Discontinued - Phase-I/II for Acute myeloid leukaemia in USA (Injection)